GeneralConnection.com ➔ Dictionary
Dictionary Search

factor ix

Synonyms

Noun

1. Christmas factor

2. factor IX, coagulation factor, clotting factor

Usage
HOPE-B Gene Therapy Holds Near-Normal Factor IX at Five Years - Docwire News
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
Novo Nordisk's Alhemo wins Korean approval for hemophilia A and B - koreabiomed.com
Etranacogene Dezaparvovec May Yield Long-Term Factor IX Expression Improvement in Hemophilia B - Hematology Advisor
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Angela Dugalic is UCLA’s X-factor - The IX Sports
Explainer 2025 Why Is Hemophilia B Called Christmas Disease - Global Biotechnology Company
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - EMJ
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
Advances in hemophilia, sickle cell disease, and thalassemia - Penn Medicine
Hemophilia B Gene Therapy Continues to Reduce Bleeding - Medscape
FDA Expands Marstacimab Indication in Hemophilia A and B - Conexiant
데일리팜코리아, 데일리팜 영문뉴스, dailypharmkorea - 데일리팜
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
Optimization of hemophilia B treatment via population PK modeling of rIX-FP, including a 3-week regimen - Frontiers
Hemophilia B drug Idelvion is now available at KHF-run clinics - koreabiomed.com
Sanofi’s hemophilia B therapy Alprolix approved for 6-month room-temperature storage - koreabiomed.com
How durable is gene therapy for haemophilia B? - Nature
Gene Therapy Supply Runs Out, Company Warns of Treatment Delays - MedPage Today
Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years - MedPage Today
B cell therapy maker Be Bio stops hemophilia trial - Endpoints News
Clinical Scenarios in Hospitalized Patients With Hemophilia - Cureus
First Patient Dosed in BeCoMe-9 Trial of BE-101 for Hemophilia B - Hematology Advisor
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years - PR Newswire
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant - The New England Journal of Medicine
How Gene Therapy Is Transforming Hemophilia B Treatment - Docwire News
Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product - Nature
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - The New England Journal of Medicine
Hemophilia Patients in Afghanistan Report Shortages of Clotting Factors - TOLOnews
Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies - Nature
Successful management with regular factor IX replacement during pregnancy in a hemophilia B carrier: A case report - obgyn.onlinelibrary.wiley.com
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B - The New England Journal of Medicine
A novel snake venom C-type lectin-like protein modulates blood coagulation by targeting von Willebrand factor and coagulation factor IX - Nature
Systemic delivery of factor IX messenger RNA for protein replacement therapy - PNAS
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence - Nature
Use of anti-haemophilia medicine suspended across Punjab after reports of adverse reactions - The Tribune
Hemophilia B Gene Therapy Demonstrates Long-Term Efficacy and Safety - Hematology Advisor
HTC Population Profile Patient Characteristics - Centers for Disease Control and Prevention | CDC (.gov)
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) - The New England Journal of Medicine
AAV gene therapy shows durable benefit in hemophilia B - 2 Minute Medicine
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space - Wiley & Sons
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Wiley Online Library
FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B - ScienceDirect.com
This gene therapy costs $5 million a dose. Is it worth the price? - SMH.com.au
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab - American Heart Association Journals
Speaking with the man, first in Canada, to receive breakthrough hemophilia B gene therapy - CTV News
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B - Biogen
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors - Nature
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - The New England Journal of Medicine
A coagulation factor moonlights in the heart - Science | AAAS
UC San Diego Health First to Offer Novel Gene Therapy for Hemophilia B - UC San Diego Health
Intellia opts out of hemophilia B gene editing work with Regeneron - Fierce Biotech
Loss of Krüppel-like factor 9 deregulates both physiological gene expression and development - Nature
Glucocorticoids increase adiposity by stimulating Krüppel-like factor 9 expression in macrophages - Nature
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response - Nature
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial - Applied Clinical Trials Online
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A - The New England Journal of Medicine
Hemophilia B Gene Therapy Produces Durable Response for 90% of Participants - AJMC
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments - Intellia Therapeutics
Press Release Service: Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B - CRISPR Medicine News
Evaluation of a New Concentrate for the Treatment of Factor IX Deficiency - The New England Journal of Medicine
Factor Levels Lower Than 50% Associated With Postpartum Complications in Patients With Hemophilia - Hematology Advisor
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector - Nature
Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A - Frontiers
Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria - Nature
Twenty-Four Novel Hemophilia B Mutations Revealed by Rapid Scanning of the Whole Factor IX Gene in a French Population Sample - Nature
Association Between Hepatic Triglyceride Content and Coagulation Factors: - American Heart Association Journals
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X - PNAS
Pulmonary Hemorrhage: An Unusual Life-Threatening Presentation of Factor IX Deficiency in a Monochorionic-Diamniotic Twin Neonate - Cureus
Fidanacogene Elaparvovec Shows Strong Results in Open-Label Phase 3 Study - AJMC
World Haemophilia Day on April 17 - Manorama Yearbook
Novel electric power-driven hydrodynamic injection system for gene delivery: safety and efficacy of human factor IX delivery in rats - Nature
Hemophilia therapy: the future has begun - Haematologica
Effective Blood Clotting Treatment:Pharmacogenomic Studies of ADAMTS13 - fda.gov
Single-dose gene therapy is potentially life-changing for adults with hemophilia B - Penn Medicine
Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice - PNAS
ASH: CSL, uniQure's gene therapy Hemgenix shows durable protection in hemophilia B - Fierce Pharma
A genetic analysis of 23 Chinese patients with hemophilia B - Nature
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
Personal Story: Carrie - Centers for Disease Control and Prevention | CDC (.gov)
Hemophilia B Gene Therapy Shows Promise in Clinical Trial - Genetic Engineering and Biotechnology News
Children's Hospital of Philadelphia Researchers Find Gene Therapy Shows Long-Term Benefits for Hemophilia B Patients - PR Newswire
Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B - 2 Minute Medicine
High Adherence, Excellent Outcomes Seen With EHL Factor VIII and IX Concentrates in Hemophilia - Hematology Advisor
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
Phase III BENEGENE-2 Trial Shows Beqvez Significantly Reduces Bleeding in Hemophilia B - Applied Clinical Trials Online
Factor IX product launched in US - MDEdge
The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A - The New England Journal of Medicine
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A - The New England Journal of Medicine
Researchers welcome $3.5-million haemophilia gene therapy — but questions remain - Nature
FDA Approves Second Gene Therapy for Hemophilia B - Medscape
Hypercoagulability in Centenarians: The Paradox of Successful Aging - ScienceDirect.com
Squarepusher | Warp Factor Nine: “For me it's about being able to operate at different speeds beyond real time” - Jazzwise
Catalyst’s Hemophilia B Gene Therapy May Be More Effective Than Padua - Hemophilia News Today
Is Hemophilia a Nosologic Entity? - ScienceDirect.com
Foreign Language Equivalents
Foreign Language Equivalents of 'factor ix'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
factor ixx,   factor i,   faxtor ix,   fatcor ix,   facter ix,   fcator ix,   factor iix,   factor ox,   ffactor ix,   facctor ix,   factor xi,   fator ix,   factorix,   dactor ix,   factor ix,   actor ix,   factorr ix,   fctor ix,   factr ix,   factoe ix,   facyor ix,   facto rix,   faactor ix,   facor ix,   factor iz,   factir ix,   facotr ix,   factor ux,   factor ic,   gactor ix,   favtor ix,   fsctor ix,   factori x,   afctor ix,   factro ix,   facttor ix,   facto ix,   factor x,   facror ix,   factot ix,   factoor ix,   factpr ix
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z